MedLearn AB
ABActiveOrg 5564686821Lövholmsvägen 18, 117 43 StockholmOther education n.e.c.· NACE 8559Est. 1993 · 33 years old100-199 employees
Loading company…
Overview
MedLearn AB is a Swedish AB based in Stockholm, operating in the Other education n.e.c. sector. Incorporated in 1993, the company reported revenue of SEK 56.8m in its latest annual filing.
Revenue 2024
56.8M SEK
+27% vs 2023
EBITDA margin
15.1 %
+106% vs 2023
Net profit 2024
0M SEK
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
44.6 %
WeakAmong the 40% lowest rated companies in the industry
20202024
Liquidity ratioCurrent assets ÷ Short-term debt
1.8×
WeakAmong the 40% lowest rated companies in the industry
20202024
Return on assets (ROA)Net profit ÷ Total assets × 100
0.0 %
WeakAmong the 40% lowest rated companies in the industry
20202024
EBITDA — year on year
SEK thousandsKey figures
Annual report 2024| Revenue | 56.8M SEK | +27% |
| EBITDA | 8.6M SEK | +106% |
| Net profit | 0M SEK | — |
| Total assets | 18.5M SEK | -2% |
| Equity | 8.3M SEK | 0% |
| Employees | — | — |
Company information
Legal name
MedLearn AB
Org number
5564686821
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
9 June 1993 · 33 years
Share capital
SEK 103,000
Employees
100-199
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva vuxenutbildning inom sjukvård, hälsovård och tandvård samt därmed förenlig verksamhet.
(no translation available)
Contact
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2024), MedLearn AB reported revenue of SEK 56.8m, an increase of 27% on the year before. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a break-even result, and the EBITDA margin stood at 15.1%.
At the end of 2024, equity financed 44.6% of the balance sheet, and current assets covered short-term debt 1.8 times.
Financials
Revenue
SEK millionsEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 56,791 | 44,755 | 43,399 | 45,814 | 48,214 |
| Staff expenses | -28,643 | — | — | — | — |
| EBITDA | 8,594 | 4,165 | 1,262 | -1,199 | -435 |
| Depreciation & amort. | -59 | -68 | -87 | -126 | -185 |
| EBIT | 8,535 | 4,097 | 1,175 | -1,325 | -620 |
| Net financials | 34 | -3 | — | -21 | 12 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 0 | 0 | 0 | 0 | 0 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | 18,500 | 18,832 | 16,094 | 16,366 | 16,903 |
| Equity | 8,253 | 8,253 | 8,253 | 8,253 | 8,253 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10,188 | 10,476 | 7,738 | 7,806 | 7,993 |
| Total debt | 10,188 | 10,476 | 7,738 | 7,806 | 7,993 |
Financial ratios
5-year trendEBITDA margin
15.1 %
20202024
Equity ratio
44.6 %
WeakAmong the 40% lowest rated companies in the industry
20202024
Return on equity
0.0 %
WeakAmong the 40% lowest rated companies in the industry
20202024
Net profit margin
0.0 %
WeakAmong the 30% lowest rated companies in the industry
20202024
Asset turnover
3.07×
Very strongAmong the 20% highest rated companies in the industry
20202024
Debt / equity
1.24×
WeakAmong the 30% lowest rated companies in the industry
20202024
Sector performance
26 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 20% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginStrong
Among the 40% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginWeak
Among the 30% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very strong
Among the 20% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 40% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 30% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalStrong
Among the 40% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 40% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 40% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityWeak
Among the 30% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityWeak
Among the 40% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 40% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 40% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 10% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery strong
Among the 20% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CO Chief Executive Officer | Chief Executive Officer | 2022 |
CA | Audit | 2021 |
Former (2)
JJ Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
JS Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
CO Board of Directors | Board of Directors | 2024 |
AE Deputy Board Member | Deputy Board Member | 2021 |
NH Chairman | Chairman | 2024 |
Former (3)
AE Board of Directors | Board of Directors | 2021 – 2022 |
JM Chairman | Chairman | 2021 – 2022 |
JS Deputy Board Member | Deputy Board Member | 2021 – 2021 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Intendia Group Sverige AB
MedLearn AB Board network connections
Board members of MedLearn AB also hold positions in 275 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Anna Ljungberg | Audit | 224 companiesMany roles |
| Nicolai Harald Løvenskiold | Chairman | 14 companiesMany roles |
| Claus Ole Forum | Chief Executive Officer | 10 companiesMany roles |
| Annika Elisabet Malmqvist | Deputy Board Member | 9 companiesMany roles |
| Jan Mikael Kaunitz | Chairman | 8 companiesMany roles |
| Anette Elisabeth Sandsjö | Board of Directors | 6 companiesMany roles |
| Jarl Johan Seltborg | Chief Executive Officer | 4 companies |
Frequently asked questions
What is the Org number of MedLearn AB?
MedLearn AB is registered with Bolagsverket / SCB under Org 5564686821.
What is the revenue of MedLearn AB?
MedLearn AB reported revenue of SEK 56.8m in 2024.
Who is the CEO of MedLearn AB?
Claus Ole Forum is the CEO of MedLearn AB, in role since 2022.
Who is the chairman of MedLearn AB?
Nicolai Harald Løvenskiold chairs the board of MedLearn AB, in role since 2024.
Where is MedLearn AB headquartered?
MedLearn AB's registered address is Lövholmsvägen 18.